Literature DB >> 9112348

Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients.

G Opelz1, Y Vanrenterghem, G Kirste, D W Gray, T Horsburgh, J G Lachance, F Largiader, H Lange, K Vujaklija-Stipanovic, J Alvarez-Grande, W Schott, J Hoyer, P Schnuelle, C Descoeudres, H Ruder, T Wujciak, V Schwarz.   

Abstract

BACKGROUND: A beneficial effect of pretransplant transfusions on graft survival was demonstrated in the early 1970s. In the mid-1980s, however, retrospective studies showed that transfusions had lost their graft-protective effect in the cyclosporine era. During the last 10 years, deliberate transfusion pretreatment of transplant patients has been discontinued.
METHODS: Within a collaborative project of 14 transplant centers, prospective recipients of cadaver kidney grafts were randomized to receive either three pretransplant transfusions or transplants without transfusions. RESULTS; The graft survival rate was significantly higher in the 205 transfusion recipients than in the 218 patients who did not receive transfusions (at 1 year: 90+/-2% vs. 82+/-3%, P=0.020; at 5 years: 79+/-3% vs. 70+/-4%, P=0.025). Cox regression analysis showed that this effect was independent of age, gender, underlying disease, prophylaxis with antilymphocyte antibodies, and preformed lymphocytotoxins. CONCLUSIONS; Transfusion pretreatment improves the outcome of cadaver kidney transplants even with the use of modern immunosuppressive regimens.

Entities:  

Mesh:

Year:  1997        PMID: 9112348     DOI: 10.1097/00007890-199704150-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  31 in total

Review 1.  Ectosomes as immunomodulators.

Authors:  Salima Sadallah; Ceylan Eken; Jürg A Schifferli
Journal:  Semin Immunopathol       Date:  2010-12-07       Impact factor: 9.623

Review 2.  Immunological consequences of apoptotic cell phagocytosis.

Authors:  Lars-Peter Erwig; Peter M Henson
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 3.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Effect of storage period of red blood cell suspensions on helper T-cell subpopulations.

Authors:  Salih H Bal; Yasemin Heper; Levent T Kumaş; Furkan Guvenc; Ferah Budak; Güher Göral; Haluk B Oral
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

Review 5.  Transfusion-associated microchimerism: the hybrid within.

Authors:  Evan M Bloch; Rachael P Jackman; Tzong-Hae Lee; Michael P Busch
Journal:  Transfus Med Rev       Date:  2012-10-24

6.  Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells.

Authors:  Matthew S Macauley; James C Paulson
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

7.  The effects of red cell transfusion donor age on nosocomial infection among trauma patients.

Authors:  Tyler J Loftus; Ryan M Thomas; Travis W Murphy; Linda L Nguyen; Frederick A Moore; Scott C Brakenridge; Philip A Efron; Alicia M Mohr
Journal:  Am J Surg       Date:  2017-07-12       Impact factor: 2.565

8.  Red blood cell supernatant potentiates LPS-induced proinflammatory cytokine response from peripheral blood mononuclear cells.

Authors:  Joel M Baumgartner; Trevor L Nydam; Jason H Clarke; Anirban Banerjee; Christopher C Silliman; Martin D McCarter
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

9.  Leukoreduced blood components: Advantages and strategies for its implementation in developing countries.

Authors:  R R Sharma; Neelam Marwaha
Journal:  Asian J Transfus Sci       Date:  2010-01

10.  Induction of Foxp3-expressing regulatory T-cells by donor blood transfusion is required for tolerance to rat liver allografts.

Authors:  Yuta Abe; Hidejiro Urakami; Dmitry Ostanin; Gazi Zibari; Tetsu Hayashida; Yuko Kitagawa; Matthew B Grisham
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.